Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL90983

TERAMEPROCOL
🧪 Phase II
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
🧪 Phase II
COc1ccc(C[C@@H](C)[C@@H](C)Cc2ccc(OC)c(OC)c2)cc1OC
ChEMBL ↗ Properties Compare Identifier

Basic Information

ChEMBL ID CHEMBL90983
Name TERAMEPROCOL
Phase Phase II
Structure Type MOL
InChI Key ORQFDHFZSMXRLM-IYBDPMFKSA-N

Known Names

EM 1421 EM-1421 EM1421 Terameprocol
9
Targets
27
Activities
2
Assay Types
4
PK Parameters
20
Publications
4
Known Names
5
Indications
1
Mechanisms

Molecular Properties

358.5
MW (Da)
4.78
ALogP
4
HBA
0
HBD
36.9
PSA (Ų)
0.65
QED
0
Ro5 Violations
9
Rot. Bonds

Drug Information

Molecule Type Small molecule
Chirality Single Enantiomer

Flags

Natural Product
USAN Year 2005

Extended Properties

Molecular Formula C22H30O4
MW 358.48
Aromatic Rings 2
Heavy Atoms 26
NP-Likeness 0.24

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
DNA inhibitor INHIBITOR DNA ✓ ✓

Indications

Central Nervous System Neoplasms Glioma Lymphoma Neoplasms Uterine Cervical Dysplasia

Activity Summary

IC50 26 meas. best 5.6
EC50 1 meas. best 4.83

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
A-375
CHEMBL613859
 IC50 5.6 5.0533 2500.0 3
Vero
CHEMBL391
 IC50 5.38 5.1257 4180.0 14
NON-PROTEIN TARGET
CHEMBL3879801
 IC50 5.3 5.3 5000.0 1
COS-1
CHEMBL614563
 IC50 4.96 4.96 11090.0 1
Human immunodeficiency virus 1
CHEMBL378
 EC50 4.83 4.83 14800.0 1
MCF7
CHEMBL387
 IC50 4.37 4.37 42400.0 2
HepG2
CHEMBL395
 IC50 4.35 4.35 44500.0 2
HT-29
CHEMBL384
 IC50 4.21 4.21 61500.0 2
HaCaT
CHEMBL614392
 IC50 4.07 4.07 85000.0 1

Pharmacokinetic Data

Parameter Value Units Species
AUC 2984.54 ng.hr.mL-1 Mus musculus
Cmax 2970.88 nM Mus musculus
Cmax 1231.59 nM Mus musculus
F 88.29 % Mus musculus

Activity Data Samples

Top measurements by pChEMBL value

Target Type Rel. Value Units pChEMBL Assay PubMed
A-375 IC50 = 2500.0 nM 5.6 Cytotoxicity against human A375 cells 19615898
Vero IC50 = 4180.0 nM 5.38 Comparative Potency (IC50s) at HSV-2 passage 1 in vero cells 9685239
Vero IC50 = 4400.0 nM 5.36 Comparative Potency (IC50s) at HSV-1 passage 2 in vero cells 9685239
Vero IC50 = 4470.0 nM 5.35 Comparative Potency (IC50s) at HSV-1 passage 10 in vero cells 9685239
NON-PROTEIN TARGET IC50 = 5000.0 nM 5.3 Cytotoxicity against human ACC375 cells 19615898
Vero IC50 = 5970.0 nM 5.22 Comparative Potency (IC50s) at HSV-1 passage 4 in vero cells 9685239
Vero IC50 = 6480.0 nM 5.19 Comparative Potency (IC50s) at HSV-1 passage 5 in vero cells 9685239
Vero IC50 = 6980.0 nM 5.16 Comparative Potency (IC50s) at HSV-1 passage 6 in vero cells 9685239
Vero IC50 = 6980.0 nM 5.16 Comparative Potency (IC50s) at HSV-1 passage 7 in vero cells 9685239
Vero IC50 = 8240.0 nM 5.08 Comparative Potency (IC50s) at HSV-1 passage 3 in vero cells 9685239
Vero IC50 = 8820.0 nM 5.05 Comparative Potency (IC50s) at HSV-1 passage 9 in vero cells 9685239
Vero IC50 = 9910.0 nM 5.0 Comparative Potency (IC50s) at HSV-1 passage 8 in vero cells 9685239
Vero IC50 = 11080.0 nM 4.96 Comparative Potency (IC50s) at HSV-2 passage 2 in vero cells 9685239
COS-1 IC50 = 11090.0 nM 4.96 Inhibitory activity against HIV Tat-regulated Transactivation in COS cells. 9685238
Vero IC50 = 11080.0 nM 4.96 Comparative Potency (IC50s) at HSV-2 passage 4 in vero cells 9685239
Vero IC50 = 11080.0 nM 4.96 Comparative Potency (IC50s) at HSV-2 passage 3 in vero cells 9685239
Vero IC50 = 11700.0 nM 4.93 Comparative Potency (IC50s) at HSV-1 passage 10 in vero cells 9685239
Human immunodeficiency virus 1 EC50 = 14800.0 nM 4.83 Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition o... 19413342
A-375 IC50 = 16600.0 nM 4.78 Cytotoxicity against human A375 cells after 5 days by MTT assay 19615898
A-375 IC50 = 16600.0 nM 4.78 Antiproliferative activity against human A-375 cells assessed as reduction in ce... 38092421

Literature References

PubMed DOI Target Context # Activities
23434529 10.1016/j.ejmech.2013.01.028 K562 20
23434529 10.1016/j.ejmech.2013.01.028 Schizosaccharomyces pombe 15
9685239 10.1021/jm980182w Vero 14
9685239 10.1021/jm980182w Unchecked 14
9685238 10.1021/jm970819w COS-1 8
28844400 10.1016/j.bmc.2017.07.047 Mycobacterium tuberculosis 6
19615898 10.1016/j.bmcl.2009.06.063 A-375 5
9685239 10.1021/jm980182w ADMET 4
38092421 10.1021/acs.jmedchem.3c01130 ADMET 4
- 10.6019/CHEMBL4495565 SARS-CoV-2 4
19615898 10.1016/j.bmcl.2009.06.063 NON-PROTEIN TARGET 3
9685239 10.1021/jm980182w Mus musculus 2
- 10.6019/CHEMBL4513161 Pseudomonas aeruginosa 2
28844400 10.1016/j.bmc.2017.07.047 Klebsiella pneumoniae 2
- 10.6019/CHEMBL4808148 Histone deacetylase 6 2
28844400 10.1016/j.bmc.2017.07.047 Escherichia coli 2
- 10.6019/CHEMBL4495564 Replicase polyprotein 1ab 2
19615898 10.1016/j.bmcl.2009.06.063 Molecular identity unknown 2
19413342 10.1021/np900123z Human immunodeficiency virus 1 1
19413342 10.1021/np900123z C8166 1

Data from ChEMBL 36 via Core Engine